The results of expanded newborn screening in the Czech Republic
Authors:
F. Votava 1; V. Kožich 2; P. Chrastina 2; K. Pešková 2; T. Adam 3; D. Friedecký 3; E. Hlídková 3; H. Vinohradská 4; P. Dejmek 1; V. Krulišová 5; A. Holubová 5; M. Balaščaková 5; T. Piskáčková 5; M. Macek 5; R. Gaillyová 6; I. Valášková 6; V. Skalická 7
Authors place of work:
Klinika dětí a dorostu, UK 3. lékařská fakulta a FN Královské Vinohrady, Prahapřednosta doc. MUDr. F. Votava, Ph. D.
1; Ústav dědičných metabolických poruch, UK 1. lékařská fakulta a Všeobecná fakultní nemocnice, Prahapřednosta prof. MUDr. V. Kožich, CSc.
2; Laboratoř dědičných metabolických poruch OKBI, UP Lékařská fakulta a FN Olomoucvedoucí doc. RNDr. T. Adam, Ph. D.
3; Oddělení klinické biochemie, pracoviště Dětská nemocnice, MU Lékařská fakulta a FN, Brnoprimář doc. MUDr. M. Dastych, CSc.
4; Ústav biologie a lékařské genetiky, UK 2. lékařská fakulta a FN Motol, Prahapřednosta prof. MUDr. M. Macek, DrSc.
5; Oddělení lékařské genetiky, MU Lékařská fakulta a FN, Brnoprimářka MUDr. R. Gaillyová, Ph. D.
6; Pediatrická klinika, UK 2. lékařská fakulta a FN Motol, Prahapřednosta prof. MUDr. J. Lebl, CSc.
7
Published in the journal:
Čes-slov Pediat 2014; 69 (2): 77-86.
Category:
Original Papers
Summary
The nationwide newborn screening (NBS) using dried blood spots (DBS) was started in 1975 for phenylketonuria//hyperphenylalaninemia (PKU/HPA); in 1985 for congenital hypothyroidism (CH); in 2006 for congenital adrenal hyperplasia (CAH) and in X/2009 screening for cystic fibrosis (CF) and 9 inherited metabolic diseases – maple syrup urine disease (MSUD), glutaric aciduria type I (GA I), isovaleric aciduria (IVA), medium chain acyl-CoA, long chain 3-hydroxyacyl-CoA and very long chain acyl-CoA dehydrogenase deficiency (MCADD, LCHADD and VLCADD), carnitine palmitoyltransferase I and II deficiency (CPTD I and II) and carnitine-acylcarnitine translocase deficiency (CACTD) was mandated.
Methods:
From 1st January 2002 through 31st December 2012 a total of 1 179,136 newborns were screened for PKU//HPA and CH; phenylalanine was measured by different methods, since X/2009 solely by tandem mass spectrometry (MS/MS); the levels of thyreotropin were measured by fluoroimmunoassay (FIA). The of 17-hydroxyprogesterone concentrations were determined in 752,922 newborns by FIA. The level of immunoreactive trypsinogen (IRT) was measured in 367,114 newborns by FIA and the CFTR gene (at first 32, later 50 most common mutations) was analysed in original DBS in 1.05% of newborns with the highest IRT levels to minimize false positive results. The spectrum of metabolites for 9 expanded inborn errors of metabolism was analysed in 362,653 newborns by MS/MS.
Results:
NS detected in total 646 patients with subsequently confirmed diagnosis. Screening prevalence were as follows PKU/HPA 1:7,234; CH 1:3,562; CAH 1:12,343; CF 1:7,060; MCADD 1:17,269; LCHADD 1:51,808; VLCADD 1:90,663; GA I 1:120,884; MSUD and IVA both 1:181,327. No case of CPTD I and CPTDII/CACTD was detected. Efficacy of NBS increased with the expansion of diseases in the programme: detection rate rose from 1:2,701 in 2002–2005 over 1:2,072 in 2007–2008 to 1:1,138 after last expansion of NBS in 2009. False positive rate (FPR) was 0.540%, of which 74% represent results of CAH screening.
Conclusion:
NBS is an effective approach for presymptomatic detection of serious rare diseases. Further optimization is a subject of current research including the introduction of additional analytical tests (second tiers) to reduce FPR and by further expanding of screened disorders.
Key words:
newborn screening, dried blood spot, prevalence, rare diseases, congenital hypothyroidism, congenital adrenal hyperplasia, cystic fibrosis, phenylketonuria, inherited metabolic disorders
Zdroje
1. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963; 32: 338–343.
2. Loeber JG, Burgard P, Cornel MC, et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1 – From blood spot to screening result. J Inherit Metab Dis 2012; 35 (4): 603–611.
3. Webové stránky NNSGRC (National Newborn Screeenig and Genetics Resource Center), http://genes-r-us.uthscsa.edu/sites/genes-r-us/files/.
4. Abstracts of the 6th European Regional Meeting in Neonatal Screening. Čes-slov Pediat 2009; 4: 159–220.
5. Hyánek J, Hoza J, Vinsová N, et al. Výsledky hromadného screeningu vrozených metabolických poruch u novorozenců. Čs Gynek 1972; 4: 208–209.
6. Blehová B, Pažoutová M, Bloudková D, et al. Zhodnocení screeningu fenylketonurie za šest let trvání laboratoře. Čes-slov Pediat 1976; 7: 399–400.
7. Hníková O, Kračmar P, Zelenka Z, et al. Screening of congenital hypothyroidism in newborns in Bohemia and Moravia. Endocrinologia Experimentalis 1989; 2: 117–123.
8. Votava F, Novotna D, Kracmar P, et al. Lessons learned from 5 years of newborn screening for congenital adrenal hyperplasia in the Czech Republic: 17-hydroxyprogesterone, genotypes, and screening performance. Eur J Pediatr 2012; 171 (6): 935–940.
9. Balascakova M, Holubova A, Skalicka V, et al. Pilot newborn screening project for cystic fibrosis in the Czech Republic: defining role of the delay in its symptomatic diagnosis and influence of ultrasound-based prenatal diagnosis on the incidence of the disease. J Cyst Fibros 2009; 8 (3): 224–227.
10. Chrastina P, Šťastná S, Myšková H, et al. Tandemová hmotnostní spektrometrie – budoucnost novorozeneckého screeningu dědičných metabolických poruch. Čes-slov Pediat 2003; 7: 464–467.
11. Chrastina P, Kostalova E, Paulova H, et al. Experience with screening by tandem mass spectrometry in the Czech Republic. The 5th European ISNS Congresss in Newborn Screening, June 10–12th 2007, Reykjavík, Island, Abstracts book, p.41.
12. Chrastina P, Bártl J, Horník P, et al. LCHAD deficiency – the most frequent fatty acid oxidation disorder in newborn screening in the Czech Republic. Čes-slov Pediat 2009; 4: 175–176.
13. Doporučení Rady Evropské unie o akci v oblasti vzácných onemocnění ze dne 8.6.2009. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:151:0007:0010:CS:PDF.
14. Usnesení Vlády ČR č. 466 ze dne 14. 6. 2010 o Národní strategii pro vzácná onemocnění na léta 2010–2020. http://www.vlada.cz/.
15. Metodický návod k zajištění celoplošného novorozeneckého laboratorního screeningu a následné péče. Věstník Ministerstva zdravotnictví ČR 2009; 6: 7–14.
16. Malikova J, Votava F, Vrzalova Z, et al. Genetic analysis of the CYP21A2 gene in neonatal dried blood spots from children with transiently elevated 17-hydroxyprogesterone. Clin Endocrinol 2012; 77 (2): 187–194.
17. Dhillon K, Ho T, Rich P, et al. An automated method on analysis of blood steroids using liquid chromatography tandem mass spectrometry: application to population screening for congenital adrenal hyperplasia in newborns. Clin Chim Acta 2011; 412 (23–24): 2076–2084.
18. Calvin J, Hogg SL, McShane D, et al. Thirty-years of screening for cystic fibrosis in East Anglia. Arch Dis Child 2012; 97 (12): 1043–1047.
19. Krulisova V, Balascakova M, Skalicka V, et al. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA. Eur J Pediatr 2012; 1 (8): 1223–1229.
20. Wilson JMG, Jungner G. Principles and practice of screening for dinase. World Health Organisation. Public Health Papers 1968; 34: 11.
21. Votava F, Strnadová KA. Novorozenecký screening v České republice a v Evropě. Čes-slov Pediat 2008; 63 (2): 96–105.
22. American College of Medical Genetics Newborn Screening Expert Group.Newborn screening: toward a uniform screening panel and systém – executive sum-mary. Pediatrics 2006; 117 (5 Pt 2): S296–S307.
23. Burgard P, Rupp K, Linder M, et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2 – From screening laboratoř results to treatment, follow-up and quality assurance. J Inherit Metab Dis 2012; 35 (4): 613–625.
24. Svaton M, Sediva A, Mejstrikova E, et al. Differential diagnostics of immunodeficiency using antigen receptor excision circles in neonatal screening cards and in postnatal peripheral blood. The 8th European Regional Meeting of International Society of Neonatal Screening, Hungary, Budapest. Orvosi Hetilap 2012; 42.
Štítky
Neonatology Paediatrics General practitioner for children and adolescentsČlánok vyšiel v časopise
Czech-Slovak Pediatrics
2014 Číslo 2
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Najčítanejšie v tomto čísle
- Complications of surgical treatment of hydrocephalus
- The results of expanded newborn screening in the Czech Republic
- Osteogenesis imperfecta associated with isolated growth hormone deficiency
- Anthropometric, hormonal and metabolic changes in prepubertal children born as SGA (small for gestational age), with decreased growth, treated with the growth hormone, after the first year of therapy